Thomas Oellerich

17PUBLICATIONS
146CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapyMedical virologyApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (17)

|Aug 31, 2026
Phosphorylation Protects Oncogenic RAS from LZTR1-Mediated Degradation.

|Jan 12, 2026
Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX).

Andreas Burchert, Franck E Nicolini, Philipp le Coutre

|Jul 18, 2024
Targeting the Sodium-Potassium Pump as a Therapeutic Strategy in Acute Myeloid Leukemia.

Constanze Schneider, Hermes Spaink, Gabriela Alexe

|Jul 18, 2024
Real-world effectiveness of first-line azacitidine or decitabine with or without venetoclax in acute myeloid leukemia patients unfit for intensive therapy.

Fabian Acker, Jörg Chromik, Emily Tiedjen

|Apr 29, 2024
Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma.

Sean R Corcoran, James D Phelan, Jaewoo Choi

|Dec 04, 2023
Cytokine-responsive T- and NK-cells portray SARS-CoV-2 vaccine-responders and infection in multiple myeloma patients.

Julius C Enssle, Julia Campe, Alina Moter

Pageof 3

Frequent Collaborators

4 joint publications

Ryan M Young

4 joint publications

James D Phelan

3 joint publications

Björn Häupl

3 joint publications

Sebastian Scheich